Meina Liang

Director, Clinical Immunology and Bioanalysis


Meina Liang

Dr. Meina Liang has broad experiences in drug development of small molecule and biologics across therapeutic areas, including antibody-drug conjugate and immunotherapy. Dr. Liang is currently director of Clinical Immunology and Bioanalysis at Medimmune, a subsidiary of AstraZeneca. She leads a centralized functional group supporting Medimmune portfolio from preclinical to post marketing, responsible for biomarker development for pharmacodynamics and patient stratification, pharmacokinetics bioanalysis for exposure-response evaluation, in vitro cytokine release testing for safety assessment, and immunogenicity assessment for regulatory submission. Her group also contributes to investigation of mechanism of action and lead selection of candidate drugs as well as development of companion diagnostics. Dr. Liang manages a GLP laboratory and also plays a DMPK project leader role for safety studies and clinical trials. She contributes to global regulatory interactions and submissions, including INDs, CTAs, IMPDs and BLAs.

Prior to joining Medimmune, Dr. Liang was a senior scientist at Abgenix, leading a centralized antibody-screening group for lead selection and characterization of therapeutic antibodies. Before Abgenix, Dr. Liang was a scientist at Berlex Biosciences, supporting small molecule drug discovery and development and played a key role in advancing a chemokine project from concept to clinical trials.

Dr. Liang holds B.S in Pharmacy from Peking University Medical School in China and Ph.D in Pharmacology from Univ. of North Carolina at Chapel Hill. She received postdoctoral training from University of Virginia. Dr. Liang is a co-inventor for a number of patents, has published numerous articles in peer-reviewed journals and has been invited to present at many international conferences.

Follow Meina Liang' at upcoming/ongoing conferences at gtcbio:

Immunogenicity & Immunotoxicity 2018